Editorial: Progress of Translational Medicine in Alzheimer's Disease

Furthermore, the analysis of GWAS data has led to identification of key pathways underlying AD pathogenesis, including cellular and metabolic processes, biological regulation, localization, transport, regulation of cellular activities, and neurological system processes. [...]gene clustering into molecular pathways may help identify novel molecular targets and support the development of more tailored and personalized intervention of AD. [...]Blevins et al. present a review article looking into the AD-related NLRP3 inflammasome, a multiprotein complex that plays a common and pivotal role in regulating innate immunity and inflammation underlying human pathophysiology. The data support CIG as a promising molecule for potentially treating AD-related tauopathy. Because type 2 diabetes (T2D) is a major contributor to the development of AD and AD patients with co-occurrence of T2D are regularly observed in the clinical arena, Carranza-Naval et al. analyze liraglutide (LRGT), a glucagon-like peptide-1 agonist, for its effects on reducing pathological changes in the brain of a mixed murine model of AD and T2D (APP/PS1 x db/db mice).